Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
ATOS's Cash-to-Debt is ranked higher than
88% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. ATOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ATOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
ATOS's Interest Coverage is ranked higher than
87% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. ATOS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATOS' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -40.73
Beneish M-Score: -10.03
WACC vs ROIC
13.36%
-1050.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -177.07
ATOS's ROE % is ranked lower than
93% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.56 vs. ATOS: -177.07 )
Ranked among companies with meaningful ROE % only.
ATOS' s ROE % Range Over the Past 10 Years
Min: -972.32  Med: -168.55 Max: -136.71
Current: -177.07
-972.32
-136.71
ROA % -136.07
ATOS's ROA % is ranked lower than
92% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. ATOS: -136.07 )
Ranked among companies with meaningful ROA % only.
ATOS' s ROA % Range Over the Past 10 Years
Min: -7246.67  Med: -123.32 Max: -102.65
Current: -136.07
-7246.67
-102.65
ROC (Joel Greenblatt) % -8751.17
ATOS's ROC (Joel Greenblatt) % is ranked lower than
97% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. ATOS: -8751.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8751.17  Med: -6849.28 Max: -1141.33
Current: -8751.17
-8751.17
-1141.33
3-Year Revenue Growth Rate -100.00
ATOS's 3-Year Revenue Growth Rate is ranked lower than
100% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ATOS: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ATOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -94 Max: 102.7
Current: -100
0
102.7
3-Year EBITDA Growth Rate -36.10
ATOS's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. ATOS: -36.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ATOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.1  Med: 6.35 Max: 54.8
Current: -36.1
-36.1
54.8
3-Year EPS without NRI Growth Rate -41.00
ATOS's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. ATOS: -41.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ATOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41  Med: 6.65 Max: 57.3
Current: -41
-41
57.3
GuruFocus has detected 2 Warning Signs with Atossa Genetics Inc $ATOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATOS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:OTCPK:MEDD, OTCPK:ABMC, NAS:ROSG, OTCPK:BZYR, OTCPK:IMEXF, OTCPK:BTHCF, OTCPK:ETAH, OTCPK:DIGP, OTCPK:OXIS, OTCPK:TBIOD, OTCPK:MTST, OTCPK:GBSN, OTCPK:PSID, OTCBB:RPBIF, NAS:TEAR, OTCPK:GNWSF, OTCPK:EXDI, NAS:ROKA, OTCPK:ILIU, OTCPK:MDIT » details
Traded in other countries:YAG1.Germany,
Headquarter Location:USA
Atossa Genetics Inc is a clinical-stage pharmaceutical company engaged in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions.

Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.

Ratios

vs
industry
vs
history
PB Ratio 1.33
ATOS's PB Ratio is ranked higher than
90% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. ATOS: 1.33 )
Ranked among companies with meaningful PB Ratio only.
ATOS' s PB Ratio Range Over the Past 10 Years
Min: 0.32  Med: 2.88 Max: 22.34
Current: 1.33
0.32
22.34
EV-to-EBIT -0.38
ATOS's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ATOS: -0.38 )
Ranked among companies with meaningful EV-to-EBIT only.
ATOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.7  Med: -1.7 Max: 0.4
Current: -0.38
-24.7
0.4
EV-to-EBITDA -0.39
ATOS's EV-to-EBITDA is ranked lower than
99.99% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. ATOS: -0.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.7  Med: -1.8 Max: 0.4
Current: -0.39
-25.7
0.4
Current Ratio 1.96
ATOS's Current Ratio is ranked lower than
61% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ATOS: 1.96 )
Ranked among companies with meaningful Current Ratio only.
ATOS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.72 Max: 16.36
Current: 1.96
0.01
16.36
Quick Ratio 1.96
ATOS's Quick Ratio is ranked lower than
55% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ATOS: 1.96 )
Ranked among companies with meaningful Quick Ratio only.
ATOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.7 Max: 16.36
Current: 1.96
0.01
16.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -45.10
ATOS's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. ATOS: -45.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.8  Med: -42.15 Max: -36.3
Current: -45.1
-45.8
-36.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.40
ATOS's Price-to-Net-Cash is ranked higher than
77% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.03 vs. ATOS: 5.40 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.26  Med: 7.36 Max: 650
Current: 5.4
2.26
650
Price-to-Net-Current-Asset-Value 2.70
ATOS's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.00 vs. ATOS: 2.70 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.14  Med: 5.4 Max: 150
Current: 2.7
2.14
150
Price-to-Tangible-Book 2.25
ATOS's Price-to-Tangible-Book is ranked higher than
84% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.16 vs. ATOS: 2.25 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.98  Med: 4.88 Max: 93.9
Current: 2.25
1.98
93.9
Earnings Yield (Greenblatt) % -263.56
ATOS's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. ATOS: -263.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -29889.1  Med: -47 Max: 6509.3
Current: -263.56
-29889.1
6509.3

More Statistics

EPS (TTM) $ -1.70
Beta1.87
Short Percentage of Float5.14%
52-Week Range $0.40 - 4.95
Shares Outstanding (Mil)7.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -2.11 -2.17 -0.70
EPS without NRI ($) -2.11 -2.17 -0.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics Initiates Additional Drug Development Program Jun 07 2016 
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capi May 27 2016 
Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update May 05 2016 
Atossa Genetics to Host First Quarter 2016 Financial Results and Company Update Conference Call on T May 03 2016 
Atossa Genetics to Host 2015 Financial Results and Company Update Conference Call on Wednesday, Marc Mar 25 2016 
Atossa Genetics Announces the Opening of Its First Phase 2 Clinical Trial of Intraductal Fulvestrant Mar 02 2016 
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary The National Reference Laboratory for Dec 17 2015 
Atossa Genetics Hires Janet Rose Rea, M.S.P.H. as VP Regulatory Affairs and Quality Oct 14 2015 
Atossa Genetics to Present at Upcoming Investor Conferences Oct 09 2015 
Atossa Genetics' Laboratory Receives ISO 15189:2012 Certification Sep 25 2015 

More From Other Websites
Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral... Jun 26 2017
ATOS: Balance Sheet Boosted by Recent Financing Jun 06 2017
Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017 Jun 01 2017
Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study May 19 2017
Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update May 11 2017
Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose... May 10 2017
Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its... May 09 2017
Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1... Apr 20 2017
Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study Apr 04 2017
Atossa Genetics Closes Public Offering Apr 03 2017
Seattle breast cancer company stock plummets as it seeks funding to continue operations Mar 29 2017
Atossa Genetics, Inc. Prices $4,000,000 Public Offering Mar 29 2017
Atossa Genetics Opens Enrollment in Study of Endoxifen Mar 23 2017
ATOS: Pure Player in the Breast Care Space Mar 17 2017
Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its... Jan 09 2017
Atossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017 Jan 05 2017
Atossa Genetics Appoints Jack Cuzick, PhD, FRS, FMedSci, FRCP (hon) as Scientific Advisor Dec 23 2016
Atossa Genetics Announces Reverse Stock Split Aug 25 2016
Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference... Aug 10 2016
Atossa Genetics Settles Litigation With Besins Healthcare Aug 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}